Explore the Agenda
Welcome to the post-conference Future of Induced Proximity Day. You can either attend our Generation Protein Modulation Day or our dedicated Novel Ligases-Targeted Drug Discovery Day. If you have any questions about the layout or agenda, feel free to reach out to us at info@hansonwade.com.
2nd Generation Protein Modulation Day
8:00 am Check-In & Morning Coffee
9:00 am Chair’s Opening Remarks
Exploring the Challenges, Learning & Opportunities Beyond Conventional Degraders to Progress the Next-Generation of Induced Proximity Therapeutics
9:15 am Panel Discussion: Exploring the Frontier Beyond Traditional Degradation: Challenges, Opportunities & Emerging Modalities
- Defining key principles for expanding the druggable proteome and identifying targets amenable to novel induced proximity strategies
- Investigating unmet needs where emerging modalities outperform traditional degradation and uncovering new therapeutic niches
- Addressing translational hurdles for novel approaches and highlighting biotech priorities in overcoming delivery, specificity and scalability challenges
- Spotlighting the most exciting new directions in induced proximity, from novel E3 ligases to non-degradative functional modulation
10:15 am Morning Break & Networking
Supercharging Novel Modalities in Translation Inhibition & Deubiquitination Expanding the Frontiers of Proximity-Based Therapeutics
11:00 am Sequence-Selective Translation Inhibition as a Novel, Proximity-Based Small Molecule Therapeutic Modality
- Drug-like small-molecule, sequence-selective interdiction of disease associated protein synthesis
- Addressing highly validated yet historically undruggable targets in oncology and neurodegeneration
- Strong reliance on machine learning fueled by biophysical characterization, cryo-EM, ribosome profiling and genomics
11:30 am Harnessing Targeted Protein Deubiquitination as a Novel Therapeutic Modality
- Overview of Stablix and targeted deubiquitination therapeutics
- Profiling novel ligands for DUB recruitment and bifunctional development
- Identifying therapeutically relevant proteins for targeted protein deubiquitination and stabilization
12:00 pm Lunch Break & Networking
1:00 pm Expanding the Frontiers of Molecular Glue Discovery: Lessons from the RAS(ON) Tri-Complex Platform
- From concept to compound: How a mechanistically informed screen enabled the discovery of RAS(ON) stabilizing molecular glues
- Assay strategy: Building a platform of biochemical, biophysical, and cell-based assays to evaluate tri-complex formation and function
- Discovery at scale: Lessons learned from integrating covalent and non-covalent screening, and the importance of resolving kinetic and cooperative effects
Expanding the Frontiers of Extracellular Protein Degradation: Engineering SORTACs, ATACs & SureTACs for Tissue-Specific Therapeutic Impact
1:30 pm Targeting Extracellular Proteins for Degradation with SORTACs to Enable Tissue-Specific Clearance
- Developing Sortilin-based lysosome-targeting chimeras (SORTACs) to enable selective extracellular protein degradation
- Designing small molecule SORTACs that degrade both soluble and membrane-bound targets with tissue and cell-type specificity
- Demonstrating SORTAC-driven clearance of pathogenic neuronal protein aggregates to open new avenues for neurodegenerative therapies
2:00 pm Afternoon Break & Networking
2:30 pm Development of Oral ATAC Degraders for Extracellular Proteins
- Harnessing natural cellular degradation machinery to eliminate pathogenic extracellular proteins ATACs (ASGPR-Targeting Chimeras)
- Discussing Avilar’s proprietary ASGPR ligands deliver superior affinity and optimized ADME properties, enabling differentiated product profiles. Also detailing from concept to candidate: Avilar’s systematic approach to developing oral ATACs
- Sharing ASGPR ligand optimization for continued improvement in oral bioavailability
- Achieving high oral bioavailability with multiple prototype ATACs targeting diverse proteins, including for Avilar’s cardiometabolic program
3:00 pm Engineering Tissue-Specific SureTACs for Targeted Cell Surface Protein Degradation
- Developing bispecific SureTAC antibodies that drive internalization and degradation of membrane proteins in a tissue- and disease-specific manner
- Harnessing the TED-I screening platform to identify high-potency E3–target pairs for enhanced degradation efficiency
- Demonstrating translational potential with preclinical data validating selective degradation of challenging membrane targets
3:30 pm Chair’s Closing Remarks
3:45 pm End of the 8th TPD & Induced Proximity Summit
Novel Ligases-Targeted Drug Discovery Day
8:00 am Check-In & Morning Coffee
9:00 am Chair’s Opening Remarks
Beyond Cereblon & VHL: Unlocking the Potential of Novel E3 Ligases to Usher in the Next Generation of Targeted Protein Degraders
9:15 am Expanding Molecular Glue Discovery with a Functional Genomics Platform for Neo-PPI Engineering
- Building a high-throughput, functional genomics-based platform to prospectively induce degradation-conducive neo-protein–protein interactions (neo-PPI)
- Unlocking novel molecular glue degraders by engineering neo-PPI beyond precedented ligase–target pairs
- Showcasing how this approach broadens the degrader discovery landscape with new mechanisms and targets
9:45 am Novel Molecular Glue Degraders of P300 & Mechanistic Characterization of Determinants of Selectivity Over Closely Related Paralog CBP
- Monovalent molecular glue degraders for histone acetyltransferase P300 (P300), a high-profile epigenetic target, were identified using Proxygen’s ligaseagnostic screening platform
- Molecular glue induces endogenous p300 degradation and modulates downstream signaling pathways recapitulating genetic dependencies in selected indications
- Ternary complex structural elucidation (Cryo-EM), Molecular Dynamics modeling, combined with biochemical and cellular characterization enabled rational drug design and optimization of preferential degradation of P300 over CREB-binding protein (CBP)
10:15 am Morning Break & Networking
11:00 am Panel Discussion: Beyond CRBN & VHL: Harnessing Novel Ligases for Next-Gen Drug Discovery
- What criteria and validation strategies should be used to determine whether a novel E3 ligase is suitable for therapeutic development?
- In what ways do novel ligases offer functional or pharmacological advantages over traditional ligases like CRBN or VHL?
- How can we build a compelling case—biologically and commercially—for prioritizing a novel ligase over established workhorses in drug development pipelines?
12:00 pm Lunch Break & Networking
Unlocking the Power of Novel E3 Ligase Discovery Platforms to Enhance Specificity, Safety & Scope of Targeted Protein Degradation
1:00 pm Harnessing the Innate Properties of Novel E3 Ligase Trim21 for the Development of Treatments for Neurodegenerative Diseases
- Why TRIM 21 is ideally suited to selectively degrading protein aggregates which underpin so many neurodegenerative diseases
- TrimTech’s approach to validating targets and TRIM21’s role in degrading these targets with a range of modalities
- TrimTech’s strategies and progress developing therapeutic degraders known as a TRIMTACTM or TRIMGLUETM for neurodegenerative and inflammatory diseases
1:30 pm Harnessing a Novel E3 Ligase-Targeting DAC to Overcome Hematologic Toxicity in ADCs
- Engineering a degrader payload that recruits a novel E3 ligase to enable selective degradation of tumor-driving proteins with reduced hematologic offtarget effects
- Advancing beyond traditional cytotoxic payloads by leveraging targeted protein degradation to minimize collateral damage to healthy blood cell lineages
- Unlocking a new class of safer, next-gen DACs with differentiated biological mechanisms to improve therapeutic index across hematologic indications
2:00 pm Afternoon Break & Networking
2:30 pm Unlocking Novel E3 Ligases with an E3-Agnostic Discovery Platform to Expand Degrader Space
- Leveraging the RaPPIDSTM platform to accelerate degrader discovery via high-throughput synthesis and phenotypic screening
- Identifying and functionally characterizing proprietary ligands that engage underexplored E3 ligases
- Enabling expansion of E3 ligase usage to unlock new biological space and accelerate pipeline progression
3:00 pm Transforming Molecular Glue Discovery with ToRNeDO: An Empirical, Cell-Based Discovery Platform
- Presenting ToRNeDO, SyntheX’s molecular glue selection platform that bypasses serendipitous screening
- Enabling functional selection of target/ligase pairs and mapping of novel degrons for rational glue design
- Discovering a molecular glue against a novel effector with exquisite target selectivity to drive new therapeutic strategies